End-stage heart failure · UK pathway
Heart transplantation in the UK, explained honestly.
A major operation with lifelong medical demands — and, for well-selected recipients, a transformative one. Delivered only through NHS Blood and Transplant, across six commissioned centres. We explain the pathway, the alternatives and the realistic expectations.
Why patients choose us
- 01
A single UK pathway, explained clearly
Heart transplantation in the UK is NHS-only, commissioned via NHS Blood and Transplant. We explain how the six centres, the waiting list, and the workup actually fit together.
- 02
Selection and alternatives, on the table
Transplant is one option for end-stage heart failure. LVAD bridge, palliative pathways and optimised medical therapy are others. We help you understand where you sit.
- 03
Independent, and free
We are not paid by any centre or manufacturer, so the guidance you get is impartial and costs you nothing.
Funding
How a UK heart transplant is funded.
Heart transplantation is commissioned by NHS England as a Highly Specialised Service and delivered through six centres. Private heart transplantation is not available in the UK.
In short
Assessment, surgery and lifelong follow-up are NHS-funded. Private second opinions and CPET are available separately.
| Stage | Funding | Typical duration | Timeframe |
|---|---|---|---|
| Heart transplant assessment (NHS) | NHS-funded | 3–5 days inpatient | Weeks to decision |
| Waiting-list management (NHS) | NHS-funded | Median 6–12 months | Ongoing |
| Heart transplant surgery + admission (NHS) | NHS-funded | 4–6 h theatre | 3–4 week stay |
| Lifelong follow-up + immunosuppression (NHS) | NHS-funded | Lifelong | Weekly → annual |
| Private second opinion (cardiology) | £350–£750 | 45–60 min | 1–2 weeks |
| Private cardiopulmonary exercise test (CPET) | £600–£1,200 | 90 min | Same visit |
Referral to a transplant centre is made by your NHS cardiologist. If you would like a private second opinion first — to confirm the diagnosis, review medical optimisation, or discuss LVAD as a bridge — we can arrange one quickly.
The problem
The right selection, the right centre, the right expectations.
Heart transplantation is one of the most tightly regulated pathways in UK medicine. Selection is strict, waiting-list mortality is real, and life afterwards is defined by lifelong immunosuppression. Understanding all three before referral matters.
-
Not sure if you meet criteria?
A private cardiology opinion can clarify LVEF, VO2, cardiac index and whether GDMT has been fully optimised — before a formal transplant assessment.
-
Worried about the wait?
Median wait is 6–12 months; 15–25% die on the list. LVAD as a bridge is discussed early where clinically appropriate.
-
Wondering about life after?
One-year survival is 85–90% and most recipients return to work — but lifelong immunosuppression, biopsies and clinic reviews are the trade-off.
The journey
From referral to lifelong follow-up — what happens, in order.
A single clinical thread from first message through assessment, listing, surgery and years of follow-up.
Phase 1 · Referral and workup
Concierge, off-stage for you
Phase 2 · Listing and surgery
Weeks to months, then the call
Phase 3 · After
Lifelong follow-up
- 01
Referral
You tell us where you are
A short, confidential form. Your diagnosis, current medications, devices already fitted (ICD, CRT, LVAD), and what your cardiologist has said so far.
- 02
Referral
We come back with a clear map
Within one working day: whether a transplant assessment is the right next step, which of the six UK centres your address falls under, and what the referral pathway looks like.
- 03
Referral
Assessment at a transplant centre
A multi-day inpatient workup: cardiology MDT, transplant surgeon, immunologist, hepatologist, psychologist and social worker. Right heart catheterisation, CPET, virology and cancer screen.
- 04
Listing / surgery
Listing on the NHSBT scheme
If accepted, you are listed on the Urgent Heart Allocation Scheme in one of three categories: super-urgent, urgent or non-urgent. Median wait is 6–12 months.
- 05
Listing / surgery
The call, and the operation
When a donor heart is found and matched, you travel to your centre. Median sternotomy, cardiopulmonary bypass, bicaval anastomosis. Four to six hours in theatre.
- 06
Listing / surgery
ITU and the transplant ward
Three to seven days in ITU, then the transplant ward. Total hospital stay is typically three to four weeks. Immunosuppression starts on day zero.
- 07
After
Life afterwards
Outpatient clinic weekly, then monthly, then less often. Endomyocardial biopsies in the first year. Cardiac rehabilitation. Lifelong immunosuppression, CMV surveillance and skin checks.
Typical timeframe: weeks for referral and assessment, 6–12 months median wait on the list, and lifelong follow-up after transplant.
When it helps
When a heart transplant is the right step.
The clinical situations that lead to transplant assessment — plus the red flag that means an emergency, not a referral.
-
End-stage heart failure, NYHA III–IV
Symptoms at rest or on minimal exertion, refractory to maximum guideline-directed medical therapy and device therapy.
-
Very reduced ejection fraction
LVEF under 25% with progressive decline despite optimised beta-blocker, ACE-i/ARNI, MRA and SGLT2 inhibitor.
-
Low cardiac index and peak VO2
Cardiac index under 2.2, peak VO2 under 14 (or under 12 if beta-blocked) on cardiopulmonary exercise testing.
-
High-risk arrhythmia
Recurrent ventricular tachycardia or fibrillation despite ICD and antiarrhythmics — a marker of poor prognosis.
-
Refractory to CRT and revascularisation
Symptoms persist despite cardiac resynchronisation therapy and appropriate revascularisation — medical options exhausted.
-
LVAD as a bridge
A left ventricular assist device may be fitted to bridge you to transplant if you deteriorate on the waiting list.
-
Paediatric heart failure
Children with end-stage congenital or cardiomyopathic disease are assessed at Great Ormond Street — different pathway, same principles.
-
Red flag: cardiogenic shock
Sudden decompensation with hypotension, cool peripheries and rising lactate needs emergency admission — same-day 999 or A&E, not a clinic booking.
Procedure options
The building blocks of a modern heart transplant.
Donor pathway, surgical technique, bridging device and immunosuppression regimen — the elements your transplant team will discuss.
-
Orthotopic heart transplant (bicaval)
The standard operation. The recipient heart is removed and the donor heart sewn in at the vena cavae — better atrial function than the older biatrial technique.
-
DBD donor (donation after brain death)
The traditional donor pathway. Cold ischaemia time kept under four to six hours, matched by blood group and size.
-
DCD donor (donation after circulatory death)
Enabled by TransMedics OCS Heart normothermic perfusion, which extends viable ischaemia time and expands the donor pool.
-
Bridge with LVAD
A durable left ventricular assist device supports the failing heart while you wait — used when deterioration is faster than the waiting list allows.
-
Induction immunosuppression
Basiliximab or ATG given around the operation to reduce the risk of early rejection while maintenance therapy is established.
-
Maintenance triple therapy
Tacrolimus plus mycophenolate mofetil plus prednisolone. Steroid dose is weaned over 6–12 months. Everolimus or sirolimus may be added for CAV or renal-sparing.
-
Endomyocardial biopsy surveillance
Six biopsies in the first year to detect rejection, then risk-based. Non-invasive monitoring with AlloMap and donor-derived cell-free DNA is emerging.
-
Cardiac rehabilitation
Structured exercise, education and psychology — the difference between surviving a transplant and living well after one.
The UK transplant network
Six centres, one national scheme.
Adult heart transplantation is delivered at Papworth (Cambridge — where the first UK heart transplant took place in 1979), Harefield (Royal Brompton), Wythenshawe (Manchester), Freeman (Newcastle) and Golden Jubilee (Glasgow). Paediatric transplants are at Great Ormond Street. Allocation is nationally coordinated by NHSBT.
How the pathway is organised
Assessment, listing and surgery are national — not private.
-
Assessment and surgery only at one of the six NHSBT-commissioned centres — Papworth, Harefield, Wythenshawe, Freeman, Golden Jubilee or Great Ormond Street
-
Multi-disciplinary team review — cardiology, transplant surgery, immunology, hepatology, psychology and social work
-
Right heart catheterisation to calculate PVR, plus CPET and virology screen, are mandatory before listing
-
Private cardiology second opinions can be arranged for symptom optimisation and prognosis — but the transplant itself is NHS only in the UK
Risks and long-term care
What life afterwards actually involves — honestly.
Heart transplantation is transformative for well-selected recipients — but it trades one set of clinical demands for another. Rejection, infection, malignancy and drug side effects are the lifelong watch-list.
-
Realistic contraindications
Fixed pulmonary hypertension (PVR >5 Wood units), active infection, recent malignancy, uncontrolled diabetes with end-organ damage, BMI over 35, active substance misuse in the last 6–12 months and poor social support are all reasons a centre may decline listing.
-
Waiting-list mortality is real
15–25% of people listed for a heart transplant die before an organ is found. LVAD bridging is offered when deterioration is faster than the list can respond.
-
Acute cellular rejection
Around 25–30% of recipients have at least one episode of acute rejection in the first year. Most are treated successfully with pulse steroids and additional immunosuppression.
-
Cardiac allograft vasculopathy (CAV)
A progressive thickening of the donor coronary arteries — the main cause of late graft failure. Statins and mTOR inhibitors reduce risk; surveillance angiography detects it early.
-
Opportunistic infection
CMV prophylaxis with valganciclovir for around 100 days, PJP prophylaxis with co-trimoxazole for six months, and vigilance for aspergillus, HHV and EBV-driven PTLD.
-
Post-transplant malignancy
Skin cancer affects more than a quarter of long-term recipients. Annual dermatology, sun protection and reduced ultraviolet exposure are essential — solid-organ cancers and PTLD are rarer but serious.
-
CKD, diabetes and hypertension
Tacrolimus, ciclosporin and steroids drive kidney injury, diabetes, hypertension and hyperlipidaemia. Up to a quarter of long-term recipients need dialysis; osteoporosis prophylaxis matters.
-
Denervation and bradycardia
The transplanted heart is denervated: it responds slowly to exercise and stress, and bradyarrhythmias occasionally need a pacemaker.
-
Red flags after transplant
Fever, breathlessness, chest pain, sudden weight gain or a rising resting heart rate are not normal — contact your transplant centre the same day.
Reading your transplant clinic letter
Your transplant letter in four parts. Read the last one first.
Whichever centre you attend, the clinic letter that lands in your inbox keeps to the same shape.
A quiet reminder
Transplant language is precise and full of acronyms — we translate it for you.
If you would like us to talk you through the letter before your next review, just ask.
- 01 Header
Diagnosis and listing category
The underlying cardiomyopathy or ischaemic aetiology, current NYHA class, and whether you have been listed super-urgent, urgent or non-urgent on the NHSBT scheme.
- 02 Technique
Donor type and surgical technique
Whether the donor was DBD or DCD, the ischaemia time, the anastomosis technique (bicaval standard), and any concurrent procedures.
- 03 Findings
Biopsy grade and CAV surveillance
ISHLT rejection grade (0R to 3R), the results of any donor-derived cell-free DNA testing, and the state of the coronaries on surveillance angiography.
- 04 Impression
Immunosuppression plan and next review
Read this first: current tacrolimus target level, prophylaxis regimens, the next biopsy or clinic date, and any medication changes.
Recognised by major UK insurers
Heart transplantation itself is NHS-funded; private insurance is used for second-opinion cardiology, CPET and outpatient investigations. We confirm cover before booking any private step.
Frequently asked
Everything we get asked about heart transplantation.
Quick answers on eligibility, the wait, the operation, survival and life on immunosuppression.
-
Can I have a heart transplant privately in the UK?
No. Heart transplantation in the UK is delivered exclusively by NHS Blood and Transplant through six commissioned centres — Papworth, Harefield, Wythenshawe, Freeman, Golden Jubilee and Great Ormond Street. Private cardiology opinions and CPET are available; the transplant itself is not.
-
Who is eligible for a heart transplant?
Adults with NYHA III or IV end-stage heart failure that is refractory to guideline-directed medical therapy, device therapy and revascularisation. Typical criteria include an LVEF under 25%, a cardiac index under 2.2, and a peak VO2 under 14 (or under 12 if beta-blocked), with no absolute contraindication.
-
What are the main contraindications?
Fixed pulmonary hypertension (PVR over 5 Wood units), active infection, recent malignancy, uncontrolled diabetes with end-organ damage, BMI over 35, active substance misuse in the last 6–12 months, severe COPD, severe CKD (creatinine clearance under 30), and lack of social support or a documented risk of non-adherence.
-
How long is the wait for a donor heart in the UK?
Median wait is 6–12 months, but ranges widely by blood group, size and listing category. Around 15–25% of people listed die before a suitable heart is found — an LVAD may be used as a bridge if deterioration is faster than the waiting list can respond.
-
What does the operation itself involve?
A median sternotomy on cardiopulmonary bypass. The recipient heart is removed and the donor heart sewn in using the bicaval technique. Cold ischaemia time is kept under four to six hours, or longer if TransMedics OCS Heart perfusion is used for a DCD donor. Theatre time is four to six hours; ITU three to seven days; hospital stay three to four weeks.
-
What are the survival figures?
One-year survival is 85–90%, five-year 70–75%, and ten-year 55–60%. Median survival is 12–14 years. Quality of life is generally excellent — most recipients return to work, exercise and normal activity, and pregnancy is possible with careful planning.
-
What are the main long-term risks?
Acute cellular rejection (25–30% in the first year), antibody-mediated rejection, cardiac allograft vasculopathy, opportunistic infection (CMV, PJP, aspergillus, PTLD from EBV), skin and solid-organ cancers, tacrolimus-related chronic kidney disease (up to a quarter need dialysis), diabetes, hypertension, hyperlipidaemia and osteoporosis from steroids.
-
What immunosuppression do transplant recipients take?
Induction with basiliximab or ATG around the operation, then lifelong maintenance triple therapy: tacrolimus, mycophenolate mofetil and prednisolone. Steroids are weaned over 6–12 months. mTOR inhibitors (everolimus, sirolimus) may be added for cardiac allograft vasculopathy or to spare the kidneys.
Related treatments
Looking for something else?
Nearby in the library